August 25, 2025 —BiotechReporter.news — Cytophage Technologies Ltd. has received Letters of No Objection from Health Canada for its OvaPhage egg surface product and PhageFend food surface product. The approvals mark a regulatory milestone for the company.
The Letters of No Objection affirm the safety and efficacy of bacteriophage technology for use in food processing. OvaPhage is in the final stages of development and advancing towards commercialization.
The notifications are a crucial step forward in granting phage products market access under a regulated path in Canada.
According to Cytophage CEO Dr. Steven Theriault, the milestone underscores the company’s commitment to eliminating bacterial diseases and infections. He added that the company aims to significantly reduce reliance on antibiotics in food systems.
Health Canada evaluated data demonstrating that OvaPhage is effective at reducing Salmonella, Escherichia, and Shigella bacteria on the surface of eggs. It also found PhageFend effective at reducing Salmonella enterica on raw skinless and boneless chicken breasts.
Cytophage is positioned to finalize the product development of OvaPhage for egg producers and PhageFend for meat processing facilities. The company continues to work with its OvaPhage commercial research partner to determine the most effective dosage and application processes for commercial settings.
The company is dedicated to bacteriophage research, product development and commercialization.
Contact: Heather Medwick, Chief Operating Officer, heather@cytophage.com | 431 388 8873
Source: Cytophage Technologies Ltd.
